---
title: "Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD)"
euct_id: 2024-517413-33-00
eudra_ct_number: 2021-003879-34
phase: Phase 4
status: Recruiting
sponsor: Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-517413-33-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-517413-33-00"
ctis_last_updated: "2026-04-23T03:31:12.815411048"
source: EU Clinical Trials Information System (CTIS)
---
# Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD)

**EU CT Number:** [2024-517413-33-00](https://euclinicaltrials.eu/ctis-public/view/2024-517413-33-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
- **Start Date:** 2023-04-01
- **Completion Date:** 2026-09-30
- **Conditions:** Idiopathic Parkinson's Disease, Parkinson's disease
- **Interventions:** ROCK_PD_low_dose, ROCK_PD_high_dose, Quinina Labesfal 250 mg/ml Solução injetável

## Member States

Trial is authorized in 1 member state: Germany.

## Sites (13)

- Universitaet Muenster, Muenster, Germany
- Katholisches Klinikum Bochum gGmbH, Bochum, Germany
- Universitaetsklinikum Tuebingen AöR, Tuebingen, Germany
- Technische Universitaet Dresden, Dresden, Germany
- Universitaetsklinikum Wuerzburg AöR, Wuerzburg, Germany
- Klinikum rechts der Isar der TU Muenchen AöR, Munich, Germany
- Universitaetsmedizin Goettingen, Goettingen, Germany
- Universitaetsklinikum Duesseldorf AöR, Duesseldorf, Germany
- Universitaet Leipzig, Leipzig, Germany
- Universitaetsklinikum Schleswig-Holstein AöR, Kiel, Germany
- Philipps-Universitaet Marburg, Marburg, Germany
- Universitaetsklinikum Erlangen AöR, Erlangen, Germany
- Medical Center - University Of Freiburg, Freiburg Im Breisgau, Germany

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Idiopathic Parkinson's Disease; Parkinson's disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-517413-33-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-517413-33-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-517413-33-00*